|Slideshows|October 28, 2016

ANA 2016: Selective Neuronal Dysfunction

Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.

Presentations at the ANA 2016 Selective Neuronal Dysfunction and Degeneration session included studies on neuronal loss in multiple system atrophy, deep brain stimulation in early Parkinson disease, treatment of transverse myelitis with dalfampridine, and a phase I trial of MSC therapy for ALS.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

ANA 2016: Selective Neuronal Dysfunction

Newsletter

Related Content

This Week on NeurologyLive® — November 3, 2025

Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240

NeurologyLive® Friday 5 — October 31, 2025

B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial

Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency

New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment

New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

Evolving Landscape of Myasthenia Gravis Treatment and Unmet Needs: Leila Darki, MD